Caris Life Sciences, Inc. (CAI)
NASDAQ: CAI · Real-Time Price · USD
28.86
+0.54 (1.91%)
At close: Dec 5, 2025, 4:00 PM EST
28.31
-0.55 (-1.91%)
After-hours: Dec 5, 2025, 6:59 PM EST
Caris Life Sciences Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Caris Life Sciences stock have an average target of 34.43, with a low estimate of 28 and a high estimate of 42. The average target predicts an increase of 19.30% from the current stock price of 28.86.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Caris Life Sciences stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Hold Initiates $28 | Hold | Initiates | $28 | -2.98% | Dec 2, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $32 → $36 | Strong Buy | Maintains | $32 → $36 | +24.74% | Aug 13, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $33 → $40 | Buy | Maintains | $33 → $40 | +38.60% | Aug 13, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $34 → $42 | Strong Buy | Maintains | $34 → $42 | +45.53% | Aug 13, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy Initiates $33 | Buy | Initiates | $33 | +14.35% | Jul 15, 2025 |
Financial Forecast
Revenue This Year
732.54M
from 412.26M
Increased by 77.69%
Revenue Next Year
994.77M
from 732.54M
Increased by 35.80%
EPS This Year
-2.51
from -10.66
EPS Next Year
0.27
from -2.51
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 768.6M | 1.1B | |||
| Avg | 732.5M | 994.8M | |||
| Low | 707.6M | 913.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 86.4% | 46.1% | |||
| Avg | 77.7% | 35.8% | |||
| Low | 71.6% | 24.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.69 | 0.48 | |||
| Avg | -2.51 | 0.27 | |||
| Low | -8.22 | 0.06 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.